NEWS AND EVENTS

28
Mar
Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)

Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB) –  Study VEL-2002 further validates solabegron’s potential for best-in-class efficacy across multiple primary and secondary endpoints   Wayne, PA – March 28, 2019 – Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated to the development of best-in-class compounds […]

Posted in: Uncategorized,
16
Oct
Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent

-Additional Funding to Advance Phase 2b Development Program in OAB- -Enrollment for Second Phase 2 Study Well Underway- -Issuance of U.S. Patent No. 10,065,922 Further Expands Velicept’s Portfolio Covering Solabegron- MALVERN, Pa.–(BUSINESS WIRE)–Velicept Therapeutics, a privately-held clinical stage pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, […]

Posted in: Uncategorized,
19
Mar
Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB

-First study has begun enrolling patients to evaluate twice-daily formulation- -Second study to begin in the second quarter to assess once-daily dosing with the novel QD formulation- -Issuance of U.S. Patent No. 9,907,767 further expands Velicept’s patent portfolio covering Solabegron- MALVERN, PA – March 19, 2018 – Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated […]

Posted in: Uncategorized,